Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Shares of Halozyme dropped 10% this morning $HALO after the company announced that AbbVie opted to drop one of their partnered programs using their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
